Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Cencora, Inc.

Get SEC filing alerts via email and in your feed for Cencora, Inc.

COR

Cencora, Inc.

About Cencora, Inc.

Cencora is a leading global pharmaceutical sourcing and distribution company serving healthcare providers and manufacturers. It offers distribution of brand-name, generic, and specialty pharmaceuticals, over-the-counter products, and related services. The company supports patient access, supply chain efficiency, and market development through logistics, consulting, and value-added solutions across the U.S. and international markets, focusing on healthcare providers, biotech firms, and animal health sectors.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Cencora, Inc.

1
1
Cencora, Inc. Cencora Reports 3.8% Revenue Growth to $78.4 Billion in Q2 Fiscal 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Cencora, Inc. Cencora Reports $85.9 Million Revenue and $566.1 Million Net Income for Q4 2025

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
Cencora, Inc. Cencora Reports 9.3% Revenue Growth to $321.3 Billion for Fiscal Year Ending September 30, 2025

Via official filing (AI summary) | 6 months ago | 0 comments

4
1
Cencora, Inc. Cencora Reports 8.7% Revenue Growth to $80.7 Billion in Latest Quarter

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Cencora, Inc. Cencora Reports 10.3% Revenue Growth to $75.5 Million in Q2 Fiscal 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Cencora, Inc. Cencora Reports 12.8% Revenue Growth to $81.5 Billion, Net Income Declines

Via official filing (AI summary) | over 1 year ago | 0 comments